Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Assembly Biosciences Inc ASMB

Healthcare Biotechnology
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle... see more

Recent & Breaking News (NDAQ:ASMB)

Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL's International Liver Congress(TM) 2022

GlobeNewswire June 22, 2022

Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022

GlobeNewswire June 21, 2022

Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL's International Liver Congress(TM) 2022

GlobeNewswire June 8, 2022

Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection

GlobeNewswire June 6, 2022

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 3, 2022

Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

GlobeNewswire May 12, 2022

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 1, 2022

Assembly Biosciences to Highlight New Research Program for HBV/HDV Entry Inhibition in Webcast on March 31, 2022

GlobeNewswire March 21, 2022

Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights

GlobeNewswire March 10, 2022

Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference

GlobeNewswire February 9, 2022

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 7, 2022

Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference

GlobeNewswire January 6, 2022

Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones

GlobeNewswire January 4, 2022

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 3, 2021

Assembly Biosciences Presents New Data at AASLD The Liver Meeting(TM) Highlighting the Progress of its HBV Core Inhibitor Portfolio

GlobeNewswire November 12, 2021

Assembly Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights

GlobeNewswire November 4, 2021

Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting®

GlobeNewswire November 1, 2021

Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration Agreement to Evaluate the Combination of ATI-2173 and Vebicorvir in Patients with Chronic Hepatitis B Virus Infection

GlobeNewswire October 19, 2021

Assembly Bio Announces October Conference Participation

GlobeNewswire October 6, 2021

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 1, 2021